Sonoma Pharma Enters Material Definitive Agreement on Jan 5

TL;DR

**Sonoma Pharma just signed a big deal, watch for details on what it means for the stock.**

AI Summary

Sonoma Pharmaceuticals, Inc. filed an 8-K on January 9, 2024, reporting a material definitive agreement entered into on January 5, 2024. This filing indicates a significant corporate action, likely a new contract or partnership, which could impact the company's future revenue or operational structure. For investors, this matters because such agreements can be catalysts for growth or, depending on the terms, introduce new risks, directly affecting the stock's valuation and potential returns.

Why It Matters

This filing signals a new, important business arrangement for Sonoma Pharmaceuticals, which could significantly alter its financial outlook and strategic direction. Investors should investigate the details of this agreement to understand its potential impact on the company's profitability and market position.

Risk Assessment

Risk Level: medium — The filing indicates a 'material definitive agreement' but lacks specific details, creating uncertainty about its financial implications and potential risks or benefits.

Analyst Insight

A smart investor would await further disclosures from Sonoma Pharmaceuticals, Inc. regarding the specifics of the 'Material Definitive Agreement' before making any investment decisions, as the current filing lacks the necessary details to assess its impact.

Key Numbers

• January 5, 2024 — Date of earliest event reported (When the material definitive agreement was entered into)
• January 9, 2024 — Date of Report (When the 8-K was filed)
• 001-33216 — Commission File Number (SEC identification for Sonoma Pharmaceuticals, Inc.)

Key Players & Entities

• Sonoma Pharmaceuticals, Inc. (company) — registrant
• The Nasdaq Stock Market LLC (company) — exchange where Common Stock is registered
• 03 Life Sciences (company) — organization name associated with the filer

FAQ

Filing Documents

• sonoma_8k.htm (8-K) — 30KB
• sonoma_ex1001.htm (EX-10.1) — 62KB
• 0001683168-24-000150.txt ( ) — 276KB
• snoa-20240105.xsd (EX-101.SCH) — 3KB
• snoa-20240105_lab.xml (EX-101.LAB) — 33KB
• snoa-20240105_pre.xml (EX-101.PRE) — 22KB
• sonoma_8k_htm.xml (XML) — 3KB

01

Item 1.01 Entry into a Material Definitive Agreement. Effective January 5, 2024, Sonoma Pharmaceuticals, Inc. (the "Company") entered into a license and distribution agreement with NovaBay Pharmaceuticals, Inc. for the sale and marketing of Avenova -branded products by the Company in the European Union. The agreement is for an initial term of two years, subject to automatic renewal periods. These products combine the Company's existing eye product Ocudox , which already has a Class IIB CE mark for sale in the European Union, with Avenova branding, and are expected to be marketed through the Company's established European distribution network. The foregoing description of the agreement is not complete and is qualified in its entirety by reference to the full text of the agreement, a copy of which is filed herewith as Exhibit 10.1. This report contains forward-looking expectations, strategies, predictions or any other statements related to the Company's future activities, or future events or conditions. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking that the Company files from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, ex

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 10.1* License and Distribution Agreement, dated January 5, 2024, by and between Sonoma Pharmaceuticals, Inc. and NovaBay Pharmaceuticals, Inc. 104 Cover Page Interactive Data File (formatted in Inline XBRL in Exhibit 101). ___________________ Certain portions of the agreement have been omitted to preserve the confidentiality of such information. The Company will furnish copies of any such information to the SEC upon request. * Some exhibits or schedules to the agreement have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish copies of any such schedule or exhibit to the SEC upon request. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SONOMA PHARMACEUTICALS, INC. Date: January 9, 2024 By: /s/ Amy Trombly Name: Title: Amy Trombly Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR